Insmed (INSM) Misses Q2 EPS by 22c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Insmed Reports Second Quarter 2021 Financial Results and Provides Business Update
August 5, 2021 7:30 AM EDTBRIDGEWATER, N.J., Aug. 5, 2021 /PRNewswire/ --Â Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the second quarter ended June 30, 2021 and provided a business update.
"Insmed made meaningful progress in the second quarter of 2021, with important achievements across our four pillarsARIKAYCE, brensocatib, TPIP, and translational medicine," commented Will Lewis, Chair and Chief Executive Officer of Insmed. "With the launch of ARIKAYCE just last month in Japan, the largest market for... More
